{
  "emaEpar": [],
  "fdaDrugLabel": [
    {
      "brand": "SYNRIBO",
      "indication": "1 INDICATIONS AND USAGE SYNRIBO is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI) ( 1 ).",
      "manufacturer": "Cephalon, Inc.",
      "splSetId": "83a504ef-cf92-467d-9ecf-d251194a3484"
    }
  ],
  "id": "Omacetaxine_Mepesuccinate",
  "nciThesaurus": {
    "casRegistry": "26833-87-4",
    "chebiId": "",
    "chemicalFormula": "C29H39NO9",
    "definition": "A semisynthetic formulation of the cytotoxic plant alkaloid homoharringtonine isolated from the evergreen tree Cephalotaxus with potential antineoplastic activity. Omacetaxine mepesuccinate binds to the 80S ribosome in eukaryotic cells and inhibits protein synthesis by interfering with chain elongation. This agent also induces differentiation and apoptosis in some cancer cell types.",
    "fdaUniiCode": "6FG8041S5B",
    "identifier": "C1127",
    "preferredName": "Omacetaxine Mepesuccinate",
    "semanticType": "Organic Chemical",
    "subclassOf": [],
    "synonyms": [
      "CGX-635",
      "Ceflatonin",
      "Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester)",
      "Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester), [3(R)]- (9CI)",
      "Cephalotaxine, 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), [3(R)]- (9CI)",
      "HHT",
      "OMACETAXINE MEPESUCCINATE",
      "Omacetaxine Mepesuccinate",
      "Synribo",
      "homoharringtonine"
    ]
  }
}